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Edited by Jesus AvilaAbstract Familial amyloidotic polyneuropathy is a neurodegen-
erative disorder characterized by systemic extracellular deposi-
tion of transthyretin (TTR) amyloid ﬁbrils. The latter have
been proposed to trigger neurodegeneration through engagement
of the receptor for advanced glycation end products (RAGE).
Here we show that TTR interaction with RAGE is conserved
across mouse and human species and is not dependent on RAGE
glycosylation. Moreover, strand D of TTR structure seems
important for the TTR–RAGE interaction as well as a motif in
RAGE (residues 102–118) located within the V-domain; this mo-
tif suppressed TTR aggregate-induced cytotoxicity in cell culture.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Transthyretin; Receptor for advanced glycation end
products; Soluble RAGE; amyloid1. Introduction
Familial amyloidotic polyneuropathy (FAP) is a hereditary
neurodegenerative disorder characterized by systemic extracel-
lular deposition of transthyretin (TTR) amyloid ﬁbrils in sev-
eral organs, mainly in the peripheral nervous system [1,2].
Several point mutations in TTR have been described to pro-
mote amyloidogenesis [3], though the most common is a sub-
stitution of a Val for Met at position 30 (V30M) [4].
Physiologically, TTR is a plasma homotetrameric protein of
55 kDa that functions as a carrier for thyroxine (T4) and ret-
inol (vitamin A) [5] by formation of a 1:1 molar complex with
retinol-binding protein (RBP).
The receptor for advanced glycation end products (RAGE)
is a member of the immunoglobulin superfamily of cell surface
molecules [6,7]. RAGE has been described as a receptor for ad-
vanced glycation end products (AGEs) [6,7], S100/calgranulins
[8], HMGB1 (amphoterin) [9], amyloid b-peptide (Ab) and for
b-sheet ﬁbrils composed of subunits such as Ab, amylin, serumAbbreviations: AGE, advanced glycation end products; FAP, familial
amyloidotic polyneuropathy; HMGB-1, high mobility group box 1
protein or amphoterin; RAGE, receptor for AGE; RBP, retinol-bin-
ding protein; sRAGE, soluble RAGE; TTR, transthyretin
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doi:10.1016/j.febslet.2006.05.020amyloid A or prion protein [10–12]. Structurally, RAGE is
composed of three extracellular immunoglobulin-like domains
(V, C, C 0-type domains), a single transmembranar domain,
and a short cytoplasmic tail that is essential for RAGE-medi-
ated signaling [6,7,13]. The V-type domain, at the amino termi-
nal, has been shown to be involved in ligand binding [14].
The secreted RAGE form, named soluble RAGE (sRAGE),
acts as a decoy to trap ligands and prevent interaction with cell
surface receptors [15]. sRAGE was shown to have important
inhibitory eﬀects in several cell culture and transgenic mouse
models, in which it prevented or reversed full-length RAGE
signaling. For instance, the administration of sRAGE has been
shown to suppress accelerated diabetic atherosclerosis [16], im-
paired wound healing [17], tumor cell migration and invasion
[18], regeneration after nerve crush [19] and accumulation of
amyloid [11].
Previous studies using recombinant sRAGE produced in
baculovirus system showed interaction with both soluble and
aggregated TTR, with a Kd of approximately 120 nM [20];
the interaction of TTR aggregates with RAGE triggers inﬂam-
matory and oxidative stress pathways [20,21]. Caspase-3 was
shown to be upregulated in axons of FAP nerves. Activation
of these markers was abrogated in cell culture by an anti-
RAGE antibody or by sRAGE [21].
Because sRAGE is a glycoprotein [22], it is likely that glyco-
sylation is important for the ability of sRAGE to interact with
its ligands. In fact, a reduction in amphoterin–RAGE binding
after RAGE deglycosylation was observed using puriﬁed
bovine RAGE [22]. The aim of this study was to characterize
the TTR interaction with a non-glycosylated sRAGE by
testing competitors such as TTR wild type and mutants,
RAGE ligands and amyloid ﬁbril ligands. In addition, we
identiﬁed a RAGE motif recognized by TTR, which might
be useful for therapeutical intervention in some RAGE-related
pathologies.2. Materials and methods
2.1. Proteins and peptides
Recombinant TTRs (i.e. human and mouse wild type (wt) TTR, and
human TTR mutants: L55P, Y78F, V30M, T119M) were produced in
an E. coli expression system and puriﬁed as previously described [23].
Puriﬁed soluble TTR was dialyzed against PBS, pH 7.4, prior to use
in binding assays. SerumRBPwas isolated using a TTR aﬃnity column.
TTR aggregates were generated by acidiﬁcation of wtTTR (2 mg/mL)
[24]. TTR ﬁbrils were produced by incubation of the aggregates for 15blished by Elsevier B.V. All rights reserved.
3452 F.A. Monteiro et al. / FEBS Letters 580 (2006) 3451–3456days at 37 C. TTR aggregates and ﬁbrils were positive by Thioﬂavin T
spectroﬂuorometric assays. Protein concentrations were determined by
the Lowry method. The human soluble RAGE cDNA (i.e. the extracel-
lular domain comprising residues 23–340) cloned in a pET32b expres-
sion vector (Novagen) was kindly provided by Dr. Larry Denner.
Soluble RAGE (sRAGE) with an amino terminal His-tag was expressed
and isolated from E. coli using HisTrap HP column (Amersham), fol-
lowing the manufacturer’s recommendations. sRAGE-His-tag was di-
gested with enterokinase (Invitrogen) and passed through a nickel
aﬃnity column to remove the His-tag product and undigested fusion
protein. A DNA fragment encoding mouse sRAGE (NCBI Accession
No. BC061182) encompassing residues 1–307 (without signal peptide)
was ampliﬁed from mouse lung cDNA with primers 5 0-CAC-
CATGCAGAACATCACAGCCCGGAT-3 0 and 5 0-GCCTTCAGCT-
GGCCCCTCATCGCCGGT-3 0 and subsequently cloned and
expressed using the pET101/D-TOPO expression system (Invitrogen).
Mouse sRAGE fusion protein with a carboxyterminal His-tag
(msRAGE-His-tag) was isolated from bacteria inclusion bodies. Brieﬂy,
msRAGE-His-tag was puriﬁed and refolded by exchange to non-denat-
urating buﬀer conditions prior to elution with imidazole (Sigma) from
the HisTrap HP column (Amersham), following the manufacturer’s
instructions. Fractions containing pure sRAGE proteins as assessed
by SDS–PAGE were combined and concentrated using Ultrafree-15
Concentrators from Milipore. Functional activity of puriﬁed human
and mouse sRAGE produced in a prokaryotic system were assessed
by binding assays to wtTTR. A RAGE peptide encompassing residues
102–118 of human RAGE extracellular ligand-binding domain [25] was
synthesized by Alta Bioscience (Birmingham). Bovine serum albumin
(BSA, fractionV; Sigma) was glycated by incubationwith 0.5 M glucose
at 37 C for 6 weeks [6]; characterization by AGE ﬂuorescence and
absorbance methods as previously described [26] conﬁrmed successful
glycation. Recombinant HMGB1 (amphoterin), >90% pure, was ob-
tained from Sigma and human serum amyloid P component (SAP),
P 99% pure, was purchased from Calbiochem.2.2. Radioligand-binding assays
Recombinant proteins were iodinated with Na125I (NEN) using the
Iodogen (Sigma) method following the supplier’s instructions. The
reaction mixture was subsequently desalted by Sephadex G50 gel ﬁltra-
tion. 125I-labelled proteins were >90% precipitable in 20% trichloroace-
tic acid and homogeneous by SDS–PAGE. Where indicated 96 well
plates (Maxisorp, Nunc) were coated with sRAGE, RAGE peptide
and ﬁbrillar (f) TTR (5 lg/well) in coating buﬀer (0.1 M bicarbonate/
carbonate buﬀer, pH 9.6) and incubated overnight at 4 C. Unoccu-
pied sites were blocked by incubation with 5% non-fat dried milk in
PBS for 2 h at 37 C. Kd assays were performed as described elsewhere
[20]. For competition studies, a constant amount of 125I-labelled pro-
teins (either sRAGE or TTR) was added to each well alone or in the
presence of the indicated molar excess of unlabelled competitors. Spe-
ciﬁc binding was deﬁned as that observed with 125I-labelled protein
alone minus 125I-labelled protein in the presence of 100-fold molar ex-
cess unlabelled protein. Binding data were ﬁt to a one-site model and
analyzed by the method of Klotz and Hunston using non-linear regres-
sion analysis with the Prism program (GraphPad Software Inc.) [20].
Results are shown as percent of maximal binding ± S.D. and are rep-
resentative of a minimum of two independent experiments.2.3. Cell culture assays
RN22 cells (rat Schwannoma cell line) were purchased from the
European Collection of Cell Cultures. RN22 were propagated for
experiments as described elsewhere [27]. Activation of caspase-3 was
measured using the ﬂuorometric caspase-3 assay kit (Sigma), following
the manufacturer’s recommendations. Brieﬂy, 80% conﬂuent cells were
incubated in assay media (DMEM containing 1% dialyzed FBS) with
2 lM of soluble or aggregated TTR for 24 h. Where indicated 10 lM
of soluble RAGE or RAGE peptide were preincubated with 2 lM
TTR aggregates in assay media for 3 h at 37 C with agitation, and
subsequently added to cells. Then, cells were trypsinized and the cell
pellet was lysed in 100 lL of kit lysis buﬀer; cell lysate samples were
assayed as described previously [27]. Values shown are the mean of
quadruplicates of two independent experiments. Student’s t test statis-
tical analysis was used to determine statistical signiﬁcance between
cells exposed to assay media and cells exposed to diﬀerent regulators
and P values of less than 0.05 were considered signiﬁcant.3. Results
3.1. Characterization of TTR–sRAGE interaction
To test the hypothesis that TTR binding to RAGE depends
on glycosylation of the receptor, we expressed human and
mouse sRAGE in a bacterial expression system. Microtiter
wells with adsorbed non-glycosylated sRAGE from human
and mouse origin bound human 125I-TTR in a dose-dependent
and saturable manner, with Kd = 376.0 ± 67.50 nM and
105.8 ± 53.45 nM, respectively (data not shown). These binding
aﬃnities are similar to values previously found for glycosylated
sRAGE i.e. a Kd of approximately 120 nM [20]. Therefore,
TTR-binding aﬃnity to RAGE is not inﬂuenced by post-tran-
scriptional modiﬁcations, such as glycosylation which occurs in
proteins expressed using the baculovirus system.
To analyze whether structural changes in TTR could aﬀect
binding aﬃnity to RAGE (both from human and mouse ori-
gins), we tested several TTR mutants and mouse TTR for
non-glycosylated RAGE binding. Among these human mu-
tants, L55P signiﬁcantly lost a competition eﬀect, showing
10-fold lower aﬃnities to both human (Fig. 1A) and mouse
(data not shown) sRAGE, as compared to human wtTTR.
Cross competition curves of human and mouse TTR for hu-
man (Fig. 1A) and mouse sRAGE binding were not signiﬁ-
cantly diﬀerent (data not shown). These data suggest that the
L55P region of TTR is relevant for RAGE binding and that
it is likely that TTR–RAGE interaction is unchanged across
mouse and human species.
It was previously shown that soluble and aggregated TTR
bind glycosylated sRAGE. We now observed that aggregated
and ﬁbrillar TTR competed with soluble TTR having similar
aﬃnities towards human sRAGE produced in bacteria
(Fig. 1B). We then questioned whether TTR and RAGE li-
gands could compete for the interaction between TTR and
non-glycosylated sRAGE. sRAGE did not bind the TTR–
RBP complex and RBP alone was not a ligand (Fig. 1B), con-
sistent with previous observations for RBP inhibition of TTR
binding to glycosylated sRAGE [20]. AGE albumin, a RAGE
ligand [6,7], competed with TTR for sRAGE binding, suggest-
ing that TTR and AGE–BSA share the same RAGE binding
site (Fig. 1B). Finally, HMGB1 (amphoterin) another RAGE
ligand [9], did not compete with TTR for sRAGE binding
(Fig. 1B). All the above binding data obtained with human
sRAGE were further conﬁrmed with mouse sRAGE, both pro-
duced in bacteria (data not shown).
The serum amyloid P component (SAP), usually present in
amyloid deposits [28], competed in a dose-dependent manner
with human sRAGE for ﬁbrillar TTR binding, which is most
probably related to the binding of SAP to amyloid ﬁbrils
(Fig. 1C). Indeed, SAP did not bind either soluble TTR or
sRAGE (data not shown).
3.2. TTR binding to RAGE peptide
A human RAGE peptide, corresponding to the 102–118
amino acid region of the RAGE V-domain, was previously re-
ported to block Ne-(carboxymethyl)lysine (CML)-induced
NFjB-driven reporter gene expression in human monocytic
THP-1 cells [25]. Thus we hypothesized that this region could
be involved in TTR binding. Indeed, 125I-TTR bound to the
RAGE peptide in a dose-dependent, speciﬁc and saturable
manner, with a Kd = 91 ± 44 nM (Fig. 2A), which is not signif-
icantly diﬀerent from observations reported using human
Fig. 1. Characterization of TTR–sRAGE interaction. (A) Displacement curves of human wild type (wt) 125I-TTR from human sRAGE produced in
bacteria by mouse and mutant TTR. 25 nM of 125I-wtTTR was added to each well in the presence of increased molar excess of one of the following
unlabelled competitors: human wtTTR, human TTR L55P and mouse wtTTR. (B) Binding of soluble 125I-TTR to human sRAGE produced in
bacteria. 4 nM of 125I-TTR was added to each well in the presence of one of the following unlabelled competitors (100-fold molar excess): soluble
TTR (sTTR); aggregated TTR (aTTR); ﬁbrillar TTR (fTTR); sTTR combined with retinol-binding protein (RBP) (sTTR–RBP); RBP alone (RBP);
AGE albumin (AGE–BSA); HMGB1; 0 denotes no addition. (C) Binding of human 125I-sRAGE produced in bacteria to ﬁbrillar wtTTR. 6 nM of
125I-sRAGE was added to each well in the presence of 0, 1, 10, 100, or 500-fold molar excess of unlabelled serum amyloid P component (SAP).
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TTR binding properties to the RAGE peptide using diﬀerent
RAGE and TTR ligands. RAGE peptide bound by decreasing
order of aﬃnity to: soluble, aggregated and ﬁbrillar TTR
(Fig. 2B). In addition, it bound to the TTR–RBP complex.B
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Fig. 2. TTR binding to RAGE peptide. (A) Binding of soluble wild type 125I-
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human sRAGE produced in baculovirus or bacteria [20]
(Fig. 1B); RBP alone did not bind (Fig. 2B). AGE–BSA com-
peted for TTR binding to RAGE peptide, further indicating
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Fig. 3. Induction of caspase-3 by TTR aggregates is inhibited by both
non-glycosylated sRAGE and RAGE peptide. Induction of caspase-3
activity in RN22 cells exposed for 24 h to 2 lM of either soluble TTR
(sTTR) or aggregated TTR (aTTR). Where indicated, cells were
incubated with 10 lM of either soluble RAGE (sRAGE) or RAGE
peptide (RAGEp). *P < 0.01, compared with untreated control.
#P < 0.01, compared with cells treated with TTR aggregates.
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(Fig. 2B).
3.3. Inhibition of TTR aggregate-induced cytotoxic eﬀects by
non-glycosylated sRAGE and RAGE peptide
A Schwannoma cell line previously used to demonstrate
RAGE mediated neurotoxicity triggered by TTR aggregates
[21], was used to determine whether non-glycosylated sRAGE
and RAGE peptide could block induction of caspase-3 by
TTR aggregates. Here we show that both non-glycosylated hu-
man sRAGE and RAGE peptide impaired TTR aggregate-in-
duced caspase-3 activation in RN22 cells (Fig. 3). Therefore,
RAGE peptide is biologically functional to block TTR aggre-
gate-induced cytotoxic eﬀects.4. Discussion
The detailed nature of RAGE-ligands interactions is pres-
ently unknown. Despite the cross competition of RAGE li-
gands for binding to the receptor [8], it is unclear whether
ligands interact with the same regions of the V-domain, or
whether a large binding pocket with several subdomains ar-
ranged in a way to optimally ﬁt diﬀerent ligand-bearing struc-
tures exists. It is important to note that all RAGE ligands
described so far appear to be multivalent, and in each case,
other cell surface receptors with which they interact have been
reported [29]. It was shown that RAGE serves as a receptor for
amyloid, as it binds ﬁbrils composed of diﬀerent subunits with
Kd  50–150 nM, such as Ab [11]. This is in accordance with
the idea that RAGE recognizes conformational structures
rather than speciﬁc amino acid sequences [29]. Such is the case
of SAP, an universal amyloid ligand [28]. SAP was capable of
competing in a dose-dependent manner with sRAGE for ﬁbril-
lar TTR binding, suggesting that RAGE and SAP recognize
the same general motif/s of amyloid ﬁbrils.
RAGE has two potential N-glycosylation sites: residues
Asn2 and Asn57, which were shown to have N-linked carbohy-
drate [30]. The residue Asn57 is located within the ligand-bind-
ing V-domain, however it was not known whether RAGE
glycosylation is needed for the interaction with b-sheet struc-
tures. In the present study we investigated the interaction ofTTR (soluble, aggregated and ﬁbrillar) with non-glycosylated
sRAGE in vitro using an established radioimmunoassay in
plastic wells [20] and found binding to all TTR species.
After screening several TTR mutants as unlabelled compet-
itors, only human L55P TTR variant displayed a 10-fold de-
creased binding aﬃnity towards human and mouse sRAGE.
This result suggests that the TTR b-strand region encompass-
ing residues 54–56 (strand D) is important in TTR–RAGE
interaction. Indeed, the L55P mutation alters the TTR second-
ary structure by disruption of the b-strand D, which becomes a
long loop that connects b-strands C and E, therefore exposing
new surfaces when compared to wild type TTR [31]. TTR crys-
tal structure revealed that each TTR monomer contains eight
b-strands, which form two sheets of four strands each, DAGH
and CBEF, arranged in a topology similar to the classic Greek
key barrel [31,32]. Due to its high b-sheet content, soluble TTR
is a good model to study the interaction of RAGE with b-sheet
ligands.
Advanced glycation end products (AGEs), the products of
nonenzymatic glycation and oxidation of proteins and lipids,
accumulate in a wide variety of biological settings such as dia-
betes, inﬂammation, and aging [33]. AGE–BSA and TTR ap-
pear to have the same RAGE-binding region, which is
independent of glycosylation, as AGE–BSA competed for
TTR–RAGE ligation; moreover, it was previously shown that
when V, C, and C 0-type domains were generated separately in
bacteria (without glycosylation modiﬁcations), solely the V-
domain inhibited binding of AGE–BSA to RAGE [14].
HMGB1 interaction with RAGE has been studied in models
such as neurite outgrowth [9], tumour cell invasion and metas-
tasis [18] and sepsis [34]. A C-terminal motif of HMGB1 (ami-
no acids 150-183) that contains an a-helix had been suggested
to be responsible for RAGE binding [35]. In the present study,
we show that HMGB1 did not inhibit TTR binding to sRAGE,
which lead us to rise the hypothesis that HMGB1 has a diﬀerent
RAGE-binding site and supports the notion that glycosylation
is relevant for HMGB1 binding to RAGE [22].
Studies with RAGE peptide recapitulated the competition
results of AGE–BSA and HMGB1 with non-glycosylated
RAGE, except for TTR–RBP complex. TTR is known to cir-
culate in plasma bound to RBP and it is likely that the TTR–
RBP complex does not interact with RAGE, as suggested by
our and previous data [20]. Sousa et al. [20] hypothesised that
this might be caused either by steric hindrance of the RBP mol-
ecule on the surface of TTR or by the fact that RAGE and
RBP might share overlapping binding sites on TTR. Our data
suggest that the TTR-binding sites for both RBP and RAGE
are close, since in contrast to sRAGE, the RAGE peptide
could interact TTR even when in a complex with RBP. In cell
culture, incubation of sRAGE or RAGE peptide, which
sequestrate RAGE ligands by acting as decoys, were able to
suppress the activation and signaling of full-length RAGE.
sRAGE inhibition of RAGE-dependent signaling may involve
besides its action as a decoy, inhibition of ﬁbrillogenesis as sug-
gested recently for Ab [36]. The diﬀerent forms of TTR (solu-
ble and aggregate) are known ligands of RAGE, and signal
transduction through RAGE is believed to play a potential
important role in the TTR pathogenesis observed in FAP
[20,21,37]. Future studies should aim at administrating RAGE
counteracting agents in FAP transgenic mouse models.
In summary, these studies indicate that not only TTR inter-
action with RAGE is not dependent on RAGE glycosylation
F.A. Monteiro et al. / FEBS Letters 580 (2006) 3451–3456 3455but also it is conserved across mouse and human species. In
addition, TTR b-strand D is important to the TTR–RAGE
interaction as well as a RAGE motif spanning residues 102–
118 located within the V-domain responsible for RAGE ligand
binding. Moreover, this RAGE motif is not involved in
HMGB1-RAGE binding; furthermore, RAGE peptide was
able to suppress TTR aggregate-induced cytotoxicity in cell
culture which may be useful for therapeutical proposes.
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